New biomarkers in IgA nephropathy.

Area of Science:

• Nephrology
• Immunology
• Biomarker Discovery

Background:

• Immunoglobulin A nephropathy (IgAN) is a leading cause of chronic kidney disease.
• Current diagnosis relies on invasive renal biopsies, limiting patient eligibility and accessibility.
• There is a critical need for non-invasive biomarkers for IgAN diagnosis and progression prediction.

Purpose of the Study:

• To review the current landscape of biomarkers for IgA nephropathy.
• To highlight the limitations of traditional diagnostic methods.
• To discuss emerging biomarkers for IgAN diagnosis, prognosis, and progression.

Main Methods:

• Literature review of IgAN diagnostic and prognostic markers.
• Analysis of traditional and novel biomarker categories.
• Discussion of galactose-deficient IgA1 (Gd-IgA1) and other emerging markers.

Main Results:

• Renal biopsy remains the gold standard but has significant limitations.
• Galactose-deficient IgA1 (Gd-IgA1) is a key target antibody.
• Emerging biomarkers include microRNAs, complement factors, proteases, inflammatory molecules, and metabolite profiles.

Conclusions:

• Non-invasive biomarkers are crucial for timely IgAN diagnosis and management.
• Advancements in biomarker research offer hope for improved patient outcomes.
• A multi-biomarker approach may enhance diagnostic accuracy and prognostic capabilities for IgAN.